Patent Term Extension Definition & Meaning | Health Care Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Patent Term Extension

Health Care Term

Patent Term Extension (PTE) is a regulatory mechanism that allows for an extension of the patent term for a specific drug or medical device. The purpose of PTE is to compensate the patent holder for the time and effort required for the drug or device to gain regulatory approval from the Food and Drug Administration (FDA).

PTE is typically used by pharmaceutical and biotechnology companies when seeking FDA approval for a new drug or biologic product that is expected to have a long development and regulatory review process. This extension provides an additional period of time, up to five years, in which to recover the expenses incurred during the development process before generic drugs can be approved.

In the healthcare industry, PTE is used to encourage investment in the development of new drugs and medical devices. It helps innovators to recuperate the costs of research and development and gives an incentive for them to invest in research and development that can lead to innovative treatments and cures for diseases.

The PTE provision in the United States was established by the Hatch-Waxman Act in 1984, and it has since been used extensively in the pharmaceutical and biotechnology industries. PTE is a valuable tool for companies seeking to bring innovative new products to market, and it provides a mechanism for ensuring that consumers have access to a steady supply of safe and effective medicines.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P